# Safety and Efficacy of Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)

> **NCT00537914** · PHASE4 · COMPLETED · sponsor: **Sandoz** · enrollment: 278 (actual)

## Conditions studied

- Small for Gestational Age

## Interventions

- **DRUG:** Omnitrope

## Key facts

- **NCT ID:** NCT00537914
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02-06
- **Primary completion:** 2022-03-25
- **Final completion:** 2022-03-25
- **Target enrollment:** 278 (ACTUAL)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00537914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00537914, "Safety and Efficacy of Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00537914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*